Glycome Atlas
concept
Also known as carbohydrate-based therapeutics, glycotherapeutics, glyco-drugs
Plain-language answer
Glycan therapeutics are medicines that are either made from sugar chains or designed to act on the sugar coatings that decorate our cells and proteins. Sugars are hard to work with as drugs because they are complex and easily broken down in the body, but they are also central to how cells recognize each other, so a growing set of vaccines, biologic drugs, and small molecules is built around them.1
Some of the most widely used medicines in the world, including several childhood vaccines and the blood thinner heparin, depend on sugar chemistry. Understanding glycans as drugs helps explain why manufacturers control the sugar content of biologic medicines so carefully and why sugar-based vaccines can protect very young children whose immune systems otherwise respond poorly to plain sugars.1
Technical detail
Glycan therapeutics is the collective term for pharmaceutical products in which carbohydrate structure is either the active principle or a critical quality attribute, encompassing polysaccharide and glycoconjugate vaccines, glycosylated protein biologics, glycosaminoglycan-derived drugs, glycomimetic small molecules, and multivalent glyco-constructs used for targeting and delivery.1
The field brings together several distinct product types: glycoconjugate and polysaccharide vaccines that present bacterial capsular sugars to the immune system, recombinant glycoprotein biologics such as therapeutic antibodies whose attached glycans influence their function, glycosaminoglycan-based agents such as heparin, and small-molecule glycomimetics that inhibit carbohydrate-processing enzymes or block sugar-lectin interactions.1
What links these otherwise different products is that carbohydrate structure is a defining feature rather than an incidental detail, which is why glycan analysis and control are embedded in their manufacture and regulation.1
Glycans are synthesized without a direct genetic template, so their structures are heterogeneous and sensitive to the producing cell line and culture conditions. This makes analytical characterization, batch-to-batch consistency, and stability against enzymatic breakdown recurring hurdles in developing carbohydrate-based medicines.1
Human relevance
Several carbohydrate-based products, including glycoconjugate vaccines and heparin anticoagulants, are established components of clinical practice, demonstrating that glycan-focused pharmaceuticals can be safe and effective at scale.1
Continue exploring
References